Compare Boston Scientific Corporation (BSX) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Southwest Airlines Co — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Southwest Airlines Co trades at $47.61 (market cap $23.25B). The key difference: Boston Scientific Corporation is far larger — about 2.9× Southwest Airlines Co's market cap, and Southwest Airlines Co pays a 1.51% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | LUV | |
|---|---|---|
Market Cap | $66.37B | $23.25B |
Sector | Health | Industrials |
52-Week High | $108.14 | $54.80 |
52-Week Low | $42.63 | $29.06 |
Enterprise Value | $75.94B | $26.31B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Southwest Airlines (LUV) trades at $47.92, down 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.47 suggesting upside. Recent earnings show a mix of beats and a miss, with Q2 2026 results expected soon. The company maintains a solid balance sheet with a debt-to-asset ratio improving to 16.86% in 2025, though net cash flow remains negative due to significant financing activities.
The outlook is cautiously optimistic, driven by potential earnings growth and cost management, but risks include fuel price volatility and competitive pressures. Analyst sentiment is mixed, with 42% buy ratings, highlighting both recovery potential and near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
